Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Verrica entered an exclusive distribution agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. Verrica will manufacture and supply the product, while Medomie seeks local regulatory approval and manages marketing. Financial terms provide Verrica with 60% of the net selling price of product sold in Israel. Verrica is also eligible to receive up to $8.2 million in total regulatory and commercial milestones.
Key figures
- Total milestones
- 8200000
- Revenue share percent
- 60
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.